Treatment that combines chemotherapy with radiotherapy.
Combined chemotherapy and radiotherapy given to augment some other form of treatment such as surgery. It is commonly used in the therapy of cancer.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Tumors or cancer of the ESOPHAGUS.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Tumors or cancer of the RECTUM.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Excision of part (partial) or all (total) of the esophagus. (Dorland, 28th ed)
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Administration of the total dose of radiation (RADIATION DOSAGE) in parts, at timed intervals.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A malignant epithelial tumor with a glandular organization.
Tumors or cancer of the NASOPHARYNX.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Antimetabolites that are useful in cancer chemotherapy.
Tumors or cancer of the HYPOPHARYNX.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Techniques, procedures, and therapies carried out on diseased organs in such a way to avoid complete removal of the organ and preserve the remaining organ function.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Tumors or cancer of the LUNG.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
An organoplatinum compound that possesses antineoplastic activity.
Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.
Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Tumors or cancer of the OROPHARYNX.
Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed)
Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Surgery performed on the digestive system or its parts.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
The area covering the terminal portion of ESOPHAGUS and the beginning of STOMACH at the cardiac orifice.
Tumors or cancer of the ANAL CANAL.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Tumors or cancer of the UTERINE CERVIX.
A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
Organic compounds which contain platinum as an integral part of the molecule.
INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
A general concept for tumors or cancer of any part of the EAR; the NOSE; the THROAT; and the PHARYNX. It is used when there is no specific heading.
CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions.
Antagonist of urate oxidase.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed)
Total or partial excision of the larynx.
Tumors or cancer of the pelvic region.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
A tubular organ of VOICE production. It is located in the anterior neck, superior to the TRACHEA and inferior to the tongue and HYOID BONE.
Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Pathological processes that affect voice production, usually involving VOCAL CORDS and the LARYNGEAL MUCOSA. Voice disorders can be caused by organic (anatomical), or functional (emotional or psychological) factors leading to DYSPHONIA; APHONIA; and defects in VOICE QUALITY, loudness, and pitch.
External or interstitial irradiation to treat lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphomas) and lymph node metastases and also some autoimmune diseases, such as rheumatoid arthritis.
Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.
The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed)
Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Elements of limited time intervals, contributing to particular results or situations.
The excision of lung tissue including partial or total lung lobectomy.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv).
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
Tumors or cancer of the STOMACH.
Transplantation of an individual's own tissue from one site to another site.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
Tumors or cancer of the PHARYNX.
The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Spasmodic contraction of the masseter muscle resulting in forceful jaw closure. This may be seen with a variety of diseases, including TETANUS, as a complication of radiation therapy, trauma, or in association with neoplastic conditions.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The vocal apparatus of the larynx, situated in the middle section of the larynx. Glottis consists of the VOCAL FOLDS and an opening (rima glottidis) between the folds.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Tumors or cancer of the NOSE.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
The use of combination of imaging techniques or platforms (e.g., MRI SCAN and PET SCAN) encompassing aspects of anatomical, functional, or molecular imaging methods.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Surgical removal of a part of the pharynx. (Dorland, 28th ed)
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
The act of taking solids and liquids into the GASTROINTESTINAL TRACT through the mouth and throat.
Used for excision of the urinary bladder.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
The period following a surgical operation.
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
Abnormal passage communicating with the ESOPHAGUS. The most common type is TRACHEOESOPHAGEAL FISTULA between the esophagus and the TRACHEA.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS.
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
The study of chance processes or the relative frequency characterizing a chance process.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
Dissection in the neck to remove all disease tissues including cervical LYMPH NODES and to leave an adequate margin of normal tissue. This type of surgery is usually used in tumors or cervical metastases in the head and neck. The prototype of neck dissection is the radical neck dissection described by Crile in 1906.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)
The return of a sign, symptom, or disease after a remission.
A subspecialty of medical oncology and radiology concerned with the radiotherapy of cancer.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Ultrasonography of internal organs using an ultrasound transducer sometimes mounted on a fiberoptic endoscope. In endosonography the transducer converts electronic signals into acoustic pulses or continuous waves and acts also as a receiver to detect reflected pulses from within the organ. An audiovisual-electronic interface converts the detected or processed echo signals, which pass through the electronics of the instrument, into a form that the technologist can evaluate. The procedure should not be confused with ENDOSCOPY which employs a special instrument called an endoscope. The "endo-" of endosonography refers to the examination of tissue within hollow organs, with reference to the usual ultrasonography procedure which is performed externally or transcutaneously.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
Tumors or cancer of the URINARY BLADDER.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
The act of dilating.
Tumors or cancer of the MOUTH.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Surgical incision into the chest wall.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
A decrease in the number of NEUTROPHILS found in the blood.
Bones that constitute each half of the pelvic girdle in VERTEBRATES, formed by fusion of the ILIUM; ISCHIUM; and PUBIC BONE.
A subnormal level of BLOOD PLATELETS.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
The period before a surgical operation.
Antibodies produced by a single clone of cells.
A subspecialty of internal medicine concerned with the study of neoplasms.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.
A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
The forcible expulsion of the contents of the STOMACH through the MOUTH.
The normal process of elimination of fecal material from the RECTUM.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
An enzyme of the transferase class that catalyzes the reaction 5,10-methylenetetrahydrofolate and dUMP to dihydrofolate and dTMP in the synthesis of thymidine triphosphate. (From Dorland, 27th ed) EC 2.1.1.45.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)

Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma. (1/605)

BACKGROUND AND OBJECTIVE: Concurrent chemoradiation therapy (CCRT) is the standard treatment for patients with locally advanced nasopharyngeal carcinoma (NPC). The effect of neoadjuvant chemotherapy followed by CCRT has not been determined. Therefore, we conducted 2 phase II studies to evaluate the efficacy and safety of neoadjuvant chemotherapy with a regimen of docetaxel, cisplatin, and 5 fluorouracil (5-Fu) (TPF) followed by radiotherapy and concurrent cisplatin in patients with stage III and IV(A - B) NPC. This article is the preliminary report on treatment related toxicities and response. METHODS: Graded according to the 2002 American Joint Committee on Cancer (AJCC) staging criteria, only patients with stage III or IV(A-B) poorly differentiated or undifferentiated NPC (World Health Organization type II/III) were included. We planned to recruit 52 patients with stage III disease and 64 patients with stage IV(A - B) disease. All patients received neoadjuvant chemotherapy with TPF (docetaxel 75 mg/m(2), day 1; cisplatin 75 mg/m(2), day 1; 5 Fu 500 mg/(m2 x day), continuous intravenous infusion for 120 h), every 3 weeks for 3 cycles, followed by weekly cisplatin (40 mg/m(2)) concurrent with radiotherapy. Three dimensional conformal radiotherapy (3D CRT) and intensity modulated radiotherapy (IMRT) were used. Gross disease planning target volume (PTV), high risk and low risk subclinical PTV doses were prescribed at 70-76 Gy, 66-70 Gy, and 60-61.25 Gy at 1.75-2.0 Gy per fraction. The lower neck or supraclavicular fields may be treated with conventional AP/PA fields for a total of 54 Gy at 1.8 Gy per fraction. Patients were evaluated for tumor response after the completion of neoadjuvant chemotherapy, and at 3 months after radiation according to the Response Evaluation Criteria In Solid Tumors (RECIST). The latest version of the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE 3.0) was used for grading all adverse events. RESULTS: Fifty nine patients were evaluable for treatment response. Thirty patients had stage III disease and 29 patients had stage IV(A-B). All patients completed RT to the prescribed dose and 2 cycles of neoadjuvant chemotherapy, with 51 patients (86.4%) completing 3 cycles. A total of 50 (84.7%) and 39 patients (66.1%) completed 4 weeks and 5 weeks of cisplatin during CCRT, respectively. The overall response rate in the primary site and the neck region were 94.9% [complete response (CR) in 25.4%] and 100% (CR in 19.6%) after completing neoadjuvant chemotherapy. At 3 months after RT, the CR rates increased to 96.6% and 90.2%, respectively. After a median follow up of 14.3 months, we observed 5 treatment failures and 2 deaths. The 1 year overall survival, distant metastasis free survival, and locoregional relapse free survival rates were 100%, 95.7%, and 97.7%, respectively. The rates of grade 3/4 myelosuppression and anorexia/nausea/vomiting during neoadjuvant chemotherapy were 55.9% and 16.9%, respectively. The corresponding rates were 11.9% and 23.7% during CCRT. Grade 3/4 mucositis, skin desquamation, and xerostomia occurred in 6.8%, 44.1%, and 27.1% of patients, respectively. There were no treatment related deaths. CONCLUSIONS: Neoadjuvant chemotherapy with TPF followed by CCRT was well tolerated with a manageable toxicity profile. Preliminary results are encouraging and warrant further investigation.  (+info)

Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. (2/605)

 (+info)

Esophageal cancer: diagnosis and management. (3/605)

Esophageal cancer is the 7th leading cause of cancer deaths worldwide. While squamous cell carcinoma is the most prevalent histology internationally, adenocarcinoma of the distal esophagus accounts for nearly 50% of cases in developed countries due to the differences in the etiologic factors such as gastroesophageal reflux disease (GERD) and obesity that predominate. While surgery is the mainstay of treatment of this disease, the utilization of chemoradiation, either used postoperatively or neoadjuvantly, has become a standard practice in the United States. What is the optimal management approach is still an area of contention, however, and may be different in different regions around the world. This article reviews some of these controversies, including the role for surgery in patients treated with definitive chemoradiation. At the end, we will also outline recommendations regarding radiotherapy procedures and techniques.  (+info)

Treatment guideline of radiotherapy for Chinese esophageal carcinoma (draft). (4/605)

Esophageal carcinoma is one of the most common human cancers in China. Radiotherapy plays an important role in combination therapy of esophageal carcinoma. With regret, there is still no unified standard for the treatment of esophageal carcinoma in China, and there are many controversies in the treatment regimens, indications, methods and efficacy. Clinically, the clinical practice guidelines of the National Comprehensive Cancer Network (NCCN) of the United States were often consulted, but the data of them were mainly from the patients from Europe and America, and they might not be applicable for Chinese patients. In order to standardize clinical process of radiotherapy for esophageal carcinoma in China, the Esophageal Carcinoma Cooperative Group of Radiation Oncology Society of Chinese Medical Association wrote a consensus and controversies on the radiotherapy for esophageal carcinoma (draft) after years of research and discussion. We hope it be tried out and discussed with advice and valuable suggestions, in order to accelerate the process of standardization of esophageal carcinoma treatment in China.  (+info)

Considerations of treatment standardization from the procession of NCCN guideline of esophageal cancer. (5/605)

Esophageal carcinoma is one of the most common malignant tumors, especially in China which is the high incidence area. As a result of mild symptoms of early-stage esophageal cancer, the majority of patients cannot be diagnosed until they develop to advanced cancer, and the treatment outcome of surgery or chemoradiotherapy is still unsatisfactory at present. The guidelines of esophageal cancer issued by National Comprehensive Cancer Network (NCCN) are regarded as important reference tools by clinical oncologists, and provide uniform criteria for the diagnosis and treatment of esophageal carcinoma. However, the guidelines are not always suitable for Chinese patients because the data come from European and American population which have significant ethnical difference from Chinese. We retrospectively analyzed the changes of treatment strategy of esophageal cancer in NCCN guidelines and the advance of treatment for esophageal carcinoma in China, aiming to provide our oncologists with new research ideas. We also hope to set up clinical cancer cooperation organizations, and release our own cancer guidelines to serve Chinese patients and oncologists.  (+info)

Literature analysis of radiotherapy for esophageal cancer in China. (6/605)

BACKGROUND AND OBJECTIVE: Many patterns of treatment have been used to treat esophageal carcinoma in the past years, however, an optimal treatment is still the key issue to be explored. Therefore, we analyzed the published literature about radiotherapy for esophageal cancer in recent 15 years in China, and observed the survival rate, local control rate, adverse events, and so on. METHODS: A total of 56 eligible papers about radiotherapy for esophageal squamous cell carcinoma published in Chinese core periodicals between 1994 and 2009 were selected. The survival rates, local control rates, and adverse events were analyzed. RESULTS: The 1-, 2-, 3-, and 5-year overall survival rates of the patients reported in the 56 papers were (67.99 +/- 12.55)%, (49.59 +/- 11.79)%, (34.50 +/- 11.49)%, and (23.31 +/- 10.21)%, respectively. The 1-, 2-, 3-, and 5-year local control rates were (73.04 +/- 13.37)%, (61.60 +/- 15.50)%, (51.77 +/- 15.00)%, and (50.15 +/- 21.36)%, respectively. The acute esophageal toxicity rate was (44.84 +/- 25.71)% in 32 papers reported in recent 15 years, and the acute esophageal toxicity over grade II accounted for (35.93 +/- 22.90)%. The rates of acute esophageal toxicity were (26.84 +/- 13.12)% for conventional radiation, (53.72 +/- 21.82)% for late course accelerated hyperfractionation radiation, (61.33 +/- 28.69)% for concurrent chemoradiotherapy, and (40.31 +/- 27.22)% for other ways of radiation. The late toxicity rate described in 23 papers was (5.13 +/- 4.07)% in recent 15 years. The late toxicity rates were (5.66 +/- 3.42)% for conventional radiation, (4.53+/- 4.07)% for late course accelerated hyperfractionation radiation, (2.24+/-1.31)% for concurrent chemoradiotherapy, and (7.34 +/- 5.06)% for other ways of radiation. The Meta analysis indicated that concurrent chemoradiotherapy was better than late course accelerated hyperfractionation radiation and conventional radiation. CONCLUSIONS: The long-term survival of patients with esophageal cancer is still disappointed in recent years. Concurrent chemoradiotherapy shows advantages in treating esophageal cancer and, currently, is the best non-surgical treatment of esophageal cancer.  (+info)

A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. (7/605)

 (+info)

Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer. (8/605)

BACKGROUND AND OBJECTIVE: Concurrent chemoradiotherapy for cervical carcinoma develops rapidly and has become a common and standard therapy in recent years. Both the local control rate and survival rate of patients were increased and the risk of death fell by 30%-50%. This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment compliance of the patients with advanced cervical squamous cell carcinoma. METHODS: A total of 156 patients with stage IIa-IIIb cervical squamous cell carcinoma were randomly divided into the concurrent chemoradiotherapy group (experimental group) and radiotherapy group (control group). Intracavity and external beam radiation therapy were administered. At point A, 40-48 Gy were given by 10-12 fractions; at point B, 46-50 Gy were given by 23-25 fractions. In the same time, experimental group was treated by cisplatin (DDP, 40 mg) on day 1, repeated every week. Ten days after radiation therapy, TP regimen was administered as adjuvant chemotherapy. RESULTS: For the experimental and control groups, the objective response rates were 88.61% and 75.32%, 1-year survival rates were 88.57% and 70.77%, 1-year local control rates were 81.43% and 64.62%, 3-year survival rates were 82.14% and 57.69%, and 3-year local control rates were 75.00% and 46.15%, with significant differences (P<0.05). Quality of life of all patients were significantly improved after treatment (P<0.05). CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and long-term survival and local control rates of patients, improve the quality of life, and the toxicity can be tolerated.  (+info)

Loco-regional recurrences after intial surgery in patients with esophageal cancer remain a serious challenge to clinical oncologists. The NCCN Guidelines pointed out that a highly selected group of patients with local-regional tumor recurrence after initial surgery may be considered fit and able to tolerate concurrent radio-chemotherapy with a potential for cure [18]. In a line with the previous studies, our data indicated that salvage concurrent radio-chemotherapy was an active and promising treatment strategy for such patients, reaching a median OS of 13.3 months with tolerable side-effects.. The present protocol of concurrent radio-chemotherapy was completed in 74% (37/50) of the patients, and no serious treatment related toxicities were observed. The tumor response rate was nearly 72% in R-TP and R-FP group respectively, with a 3-year survival rate of 14%. These results are very similar to those reported in previous studies [13, 15]. Yamashita et al.[13] reported the results of radiotherapy ...
TY - JOUR. T1 - Adjuvant therapy in colorectal cancer. A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with methanol extraction residue of BCG, MER. AU - Robinson, E.. AU - Bartal, A.. AU - Cohen, Y.. AU - Milstein, D.. AU - Mekori, T.. PY - 1979/12/1. Y1 - 1979/12/1. N2 - Fifty-three patients with colorectal cancer (Dukes B 2 and C) were randomized after surgery. One group was treated by radio-and/or chemotherapy and the second by radio-and/or chemotherapy and MER. After 24 and 36 months a significant longer disease free interval, lower recurrence rate and better survival was found in the group treated by radio-chemo-and immunotherapy. Treatment was well tolerated and there were few local side effects from the MER injections. The long time efficacy of this adjuvant treatment whether it increases the cure rate or only delays recurrence requires longer follow-up.. AB - Fifty-three patients with colorectal cancer (Dukes B 2 and C) were randomized after surgery. ...
A single center prospective observational study will be performed in esophageal cancer patients. This study registers motion of the esophageal tumor, using 4D planning CT scans and repeated 4D CBCT scanning. Motion of fiducial markers inserted into the esophageal wall, will be used as a surrogate for tumor motion in the limited image quality of CBCT scans.. Patients planned for trimodality treatment will additionally be imaged by serial 4D Pet CT and MRI in week 0 (before start chemoradiotherapy), week 3 (during chemoradiotherapy) and week 10 (just prior to surgery) to observe (early) signs of tumor response.. Patients planned for definitive chemoradiation will not receive extra MRI imaging during treatment because of the inability to correlate this imaging with pathological response. ...
Preoperative chemoradiotherapy followed by radical surgical resection represents the standard of care for patients with locally advanced rectal cancer (4, 11, 26). However, the response of individual tumors to preoperative multimodal treatment is highly heterogeneous and ranges from complete clinical response to absence of any histopathologic tumor regression (complete resistance). This poses a clinical dilemma, because patients with resistant tumors are exposed to the potential side effects of chemotherapy and irradiation with no clear benefit. It is therefore critical to uncover mechanisms and pathways of treatment resistance for the identification of strategies to increase the fraction of patients with rectal cancer who benefit from multimodal neoadjuvant treatment (10).. In an attempt to identify novel molecular targets and pathways that may be manipulated to sensitize tumors to chemoradiotherapy, we previously demonstrated that the Wnt transcription factor TCF7L2 is overexpressed in ...
A phase 3 noninferiority study has found that in patients with nonoperable locally advanced squamous cell cancer of the head and neck, concurrent chemoradiotherapy remains the standard treatment, according to results presented at the ASCO 2016 Annual Meeting.
Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
TY - JOUR. T1 - A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer. AU - Nikas, Jason B.. AU - Lee, Janet T.. AU - Maring, Elizabeth D.. AU - Washechek-Aletto, Jill. AU - Felmlee-Devine, Donna. AU - Johnson, Ruth A.. AU - Smyrk, Thomas C.. AU - Tawadros, Patrick S.. AU - Boardman, Lisa A.. AU - Steer, Clifford J. PY - 2015/1/1. Y1 - 2015/1/1. N2 - An important determinant of the pathogenesis and prognosis of various diseases is inherited genetic variation. Single-nucleotide polymorphisms (SNPs), variations at a single base position, have been identified in both protein-coding and noncoding DNA sequences, but the vast majority of millions of those variants are far from being functionally understood. Here we show that a common variant in the gene MTHFR [rs1801133 (C,T)] not only influences response to neoadjuvant chemoradiotherapy in patients with rectal cancer, but it also influences recurrence of the disease itself. More specifically, patients with ...
A B S T R AC T BACKGROUND The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well
CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study
After matching at a 1:2 ratio, 150 patients were treated with CCRT and 75 with CCRT plus C were selected. The 3-year PFS rates (83.7% vs 72.0%, P = 0.036) and 3-year LRFS rates (98.6% vs 90.2%, P = 0.034) were higher for patients in the CCRT plus C arm than with CCRT alone. Furthermore, a marginal trend of increasing risk of 3-year DMFS rates (83.9% vs 78.4%, P = 0.301) and 3-year OS rates (91.2% vs 85.8%, P = 0.123) was found. The results indicated that CCRT plus C treatment was a significant and independent protective predictor for 3-year PFS (P = 0.015) and LRFS rates(P = 0.047). When focusing on stage T4 and/or N3 in the subgroup, the CCRT plus C arm achieved significantly prolonged 3-year PFS (79.9% vs 62.6%, P = 0.022) and a marginally increased OS (88.0% vs 77.9%, P = 0.086) compared with that of CCRT alone. Additionally, the 3-year LRFS (97.0% vs 90.9%, P = 0.246) and DMFS (79.9% vs 67.8%, P = 0.161) were enhanced in patients with CCRT plus C compared to CCRT alone. When concentrating on ...
The purpose of this study is to evaluate the efficiency and safety of weekly Cisplatin /Liposome paclitaxel concurrent chemoradiothrapy in the treatment
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
In this phase I trial neoadjuvant CCRT combining IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and BV-fluorouracil/ le
Findings from a recent study demonstrate that the PD-L1 inhibitor durvalumab demonstrated statistically significant and clinically meaningful improvement in
The EORTC QLQ-LC13 is a lung cancer specific module from the EORTC comprising 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, chest pain, arm/shoulder pain, and other pain), treatment related side-effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores from 0 to 100 were derived for each symptom item with higher scores representing greater symptom severity. Time to symptom deterioration was defined as time from randomization until the date of first clinically meaningful symptom deterioration (an increase in the score from baseline of ≥10) or death (by any cause) in the absence of a clinically meaningful symptom deterioration. Results are presented for time to deterioration in the following PRO endpoints identified as primary for EORTC QLQ-LC13: dyspnea, cough, hemoptysis and chest pain. Time to deterioration was calculated using the Kaplan-Meier technique ...
TY - JOUR. T1 - Trans oral robotic surgery versus definitive chemoradiotherapy for oropharyngeal cancer. T2 - 10-year institutional experience. AU - Meccariello, Giuseppe. AU - Bianchi, Giulia. AU - Calpona, Sebastiano. AU - Parisi, Elisabetta. AU - Cammaroto, Giovanni. AU - Iannella, Giannicola. AU - Sgarzani, Rossella. AU - Montevecchi, Filippo. AU - De Vito, Andrea. AU - Capaccio, Pasquale. AU - Pelucchi, Stefano. AU - Vicini, Claudio. PY - 2020/11. Y1 - 2020/11. N2 - Objectives: Trans Oral Robotic Surgery (TORS) is a fascinating new technique that has proved to be a safe and feasible treatment of oropharyngeal squamous cell carcinoma (OPSCC). The aim of this study is to compare oncological outcomes of OPSCC-patients treated with either TORS (with or without adjuvant therapy) or definitive chemoradiation therapy (CRT). Materials and methods: This study involved 129 patients with OPSCC, treated with TORS or definitive CRT at our Department between 2008 and 2018. Clinicopathological ...
In an observational study reported in JAMA Oncology, Kelly et al found that overall survival was similar with upfront surgery and definitive chemoradiotherapy among patients with newly diagnosed cT1-2 N1-2b human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma.. Study Details. The study involved 1,044 patients from the National Cancer Database who were newly diagnosed between 2010 and 2012. Among them, 460 patients (44.1%) received upfront surgery, and 584 patients (55.9%) received chemoradiotherapy. Median age was 59 years (range, 25-90 years), and 77.8% were male. Adjuvant chemoradiotherapy was received by 59% of surgical patients.. Survival Outcomes. Median follow-up was 30 months. Overall, 3-year overall survival was 81.4% in the surgery group vs 79.2% in the chemoradiotherapy group (P = .65). On multivariable analysis, the adjusted hazard ratio for death for surgery vs chemoradiotherapy was 1.01 (P = .93). In a propensity score-matched cohort of 822 patients, the hazard ...
BACKGROUND: The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results. METHODS: In a multicenter trial using a two-by-two factorial design, we randomly assigned 73 patients with resected pancreatic ductal adenocarcinoma to treatment with chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil), 75 patients to chemotherapy alone (fluorouracil), 72 patients to both chemoradiotherapy and chemotherapy, and 69 patients to observation. RESULTS: The analysis was based on 237 deaths among the 289 patients (82 percent) and a median follow-up of 47 months (interquartile range, 33 to 62). The estimated five-year survival rate was 10 percent among patients assigned to receive chemoradiotherapy and 20 percent among patients who did not receive chemoradiotherapy (P=0.05). The five-year survival rate was 21 percent among patients who received chemotherapy and 8
A three-step treatment plan incorporating adoptive immunotherapy and chemoradiotherapy was used to treat AKR (H-2k) mice bearing spontaneous leukemia-lymphoma (SLL). 1) Leukemic mice were treated with chemoradiotherapy for immunosuppression and leukemia cytoreduction. 2) To introduce a graft-versus-leukemia reaction against residual malignant cells, the immunosuppressed AKR mice were given immunocompetent cells from H-2 mismatched DBA/2 (H-2d) donors. 3) To rescue the AKR hosts from incipient graft-versus-host disease, the mismatched DBA/2 cells were killed with combination chemotherapy, and cells from allogeneic H-2 matched RF (H-2k) donors were administered to restore hematopoiesis. Leukemic AKR mice thus treated had significant prolongation of their median survival time and a higher 60-day survival rate post treatment than did untreated controls, chemoradiotherapy controls, or control mice that received chemoradiotherapy plus cells from syngeneic donors. Therefore, adoptive immunotherapy ...
TY - JOUR. T1 - Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer. AU - Ohnishi, Kayoko. AU - Shioyama, Yoshiyuki. AU - Nakamura, Katsumasa. AU - Nakashima, Torahiko. AU - Ohga, Saiji. AU - Nonoshita, Takeshi. AU - Yoshitake, Tadamasa. AU - Terashima, Kotarou. AU - Komune, Shizuo. AU - Honda, Hiroshi. PY - 2011/2/14. Y1 - 2011/2/14. N2 - Purpose: S-1 is an oral fluoropyrimidine. The purpose of this study was to review the clinical outcomes of S-1 with concurrent radiotherapy for patients with oropharyngeal cancer. Materials and Methods: Between 2002 and 2007, 38 patients with oropharyngeal cancer treated concurrently with S-1 and definitive radiotherapy were reviewed. The clinical stage was Stage I in 4 patients, Stage II in 7, Stage III in 7, and Stage IV in 20. S-1 was administered orally twice daily for 4 consecutive weeks followed by a 2-week drug withdrawal. The initial dose of S-1 was 65 mg/m2/day. All patients were treated using ...
This study investigated the role of hyperthermia combined with preoperative concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer (LARC) according to hypoxic marker expression. One hundred and nine LARC patients with tissue blocks available for immunohistochemical assessment of carbonic anhydrase 9 (CA9) expression were reviewed. CA9 expression was considered positive when the staining percentage of tumor cells was |25% (n = 31). Pelvic radiotherapy with a total dose of 39.6-45 Gy was delivered concurrently with fluorouracil-based chemotherapy. Hyperthermia was administered to 52 patients twice a week during CCRT. Treatment response and outcomes were compared between hyperthermochemoradiotherapy (HCRT) and CCRT groups. In patients with positive CA9 expression, the rates of downstaging (p = 0.060) and pathologic complete response (p = 0.064) tended to be higher in the HCRT group than in the CCRT group. Distant metastasis-free survival (p = 0.029) and cancer-specific survival (p = 0.020)
Thirty-one patients were recruited according to the Simons two-stage design method. The median age was 62 years (range, 41-74) and the primary site was oropharynx; 11 (35%), hypopharynx; 18 (58%), larynx; 2 (7%). Twenty-four patients (77%) completed chemoradiotherapy as planned, and 9 patients (29%) completed adjuvant TPF chemotherapy. Thirty patients were evaluated for response without 1 early death before post-treatment assessment, and the response rates were CR, 10%; PR, 66.7%; SD, 6.7%; PD, 16.6%. At a median follow-up of 31 months (range, 4.5-113), the median time to progression and overall survival was 13.2 months (95% CI, 7.6-22.4) and 39.9 months (95% CI, 15.7-), respectively. The estimated overall survival with functional larynx at 3 years was 35.5% (95% CI, 20.9-53.4). The most common grade 3 or 4 adverse events during the treatment were lymphocytopenia (100%), mucositis (77%), pain (45%), hyponatremia (32%) and leukocytopenia (13%). Toxicities related to the kidney were minimal and ...
TY - JOUR. T1 - Completion surgery after chemoradiotherapy for cervical cancer-is there a role? UK Cancer Centre experience of hysterectomy post chemo-radiotherapy treatment for cervical cancer. AU - Platt, Sarah L.. AU - Patel, Amit. AU - Humphrey, Pauline J.. AU - Al-Booz, Hoda. AU - Bailey, Jo. PY - 2019/1/2. Y1 - 2019/1/2. N2 - The standard treatment for locally advanced cervical cancer is chemo-radiotherapy. The presence of the residual disease after treatment is directly related to the relapse risk and to poor survival. There is a lack of consensus on the role of a subsequent surgery due to morbidity concerns. Oncological and peri-operative outcomes of completion surgery for cervical cancer were reviewed by retrospective descriptive analysis of the eligible cases between March 2012 and March 2016. Fifteen women were identified. Ten (66.7%) had a residual tumour on their post-treatment MRI. Surgical histology indicated a residual cancer in 26.7%. There were three distant recurrences. Bowel ...
The purpose of this study was to compare outcomes in patients with anal canal squamous cell carcinoma (SCCA) who were treated with definitive chemoradiotherapy by either intensity-modulated radiation therapy (IMRT) or conventional radiotherapy (CRT).Forty-six patients who received definitive chemoradiotherapy from January 1993 to August 2009 were included. Forty-five patients received 5-fluorouracil with mitomycin C (n = 39) or cisplatin (n = 6). Seventeen (37%) were treated with CRT and 29 (63%) with IMRT. The median dose was 54 Gy in both groups. Median follow-up was 26 months (CRT) and 32 months (IMRT). T3-T4 stage (P = .18) and lymph node-positive disease (P = .6) were similar between groups.The CRT group required longer treatment duration (57 days vs 40 days, P , .0001), more treatment breaks (88% vs 34.5%, P = .001), and longer breaks (12 days vs 1.5 days, P , .0001) than patients treated with IMRT. Eleven (65%) patients in the CRT group experienced grade ,2 nonhematologic toxicity ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Carcinoma, Patients, Organ Preservation, Surgery, Cell, Chemoradiotherapy, Concurrent Chemoradiotherapy, Platinum, Squamous Cell Carcinoma, Cancer, Eating, Fatigue, Future, Life, Morbidity, Mouth, Organization, Pain, Quality Of Life, Questionnaires
This trial will investigate the tolerability and preliminary efficacy of midostaurin + chemoradiotherapy (fluorouracil + radiotherapy) in patients with locally
This study determined the maximum tolerated dose (MTD) and the recommended dose (RD) according to dose limiting toxicity (DLT).This study evaluated the
Dr. Abbas and colleagues delineate the current status of chemoradiation for anal carcinoma. Their thorough and thoughtful review serves as an excellent summation of the current therapeutic approach of the past few years. 1
Musculoskeletal notes and revision materials. We also stock notes on Paediatrics as well as Medicine Notes generally. Why not see if you can find something useful?
In a Chinese phase III trial reported in The New England Journal of Medicine, Yuan Zhang, MD, PhD, and colleagues found that the addition of gemcitabine/cisplatin induction chemotherapy to standard platinum-based chemoradiotherapy improved recurrence-free survival vs chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma.. Study Details. The open-label trial included 480 patients with newly diagnosed disease from 12 centers. Patients were randomly assigned between December 2013 and September 2016 to receive gemcitabine at 1 g/m2 on days 1 and 8 and cisplatin at 80 mg/m2 on day 1 every 3 weeks for three cycles plus standard chemoradiotherapy (n = 242) or standard chemoradiotherapy alone (n = 238). Chemoradiotherapy consisted of 100 mg/m2 of cisplatin every 3 weeks on days 1, 22, and 43, plus intensity-modulated radiotherapy. Randomization was stratified by treatment center and disease stage III or IV. It was recommended that patients in the induction chemotherapy group begin ...
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide. Surgery alone cannot obtain satisfactory effects in patients with EC. Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs) have been published, but opinions vary among clinicians as to the therapeutic effect of the new method. It remains uncertain whether patients with resectable EC can benefit from neoadjuvant chemoradiotherapy.. A research article to be published on December 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team from China selected eleven randomized controlled trials (RCTs) including 1308 patients. The reuslts showed neoadjuvant chemoradiotherapy significantly improved the overall survival compared with surgery alone. Histological subgroup analysis indicated that esophageal squamous cell carcinoma did not benefit from neoadjuvant chemoradiotherapy.. Their meta-analysis suggest that patients ...
TY - JOUR. T1 - Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. AU - Choi, Hye Jin. AU - Kim, Nam Kyu. AU - Keum, Ki Chang. AU - Cheon, Seong Ha. AU - Shin, Sang Jun. AU - Baik, Seung Hyuk. AU - Choen, Jae Hee. AU - Rha, Sun Young. AU - Roh, Jae Kyung. AU - Jeung, Hei Cheul. AU - Chung, Hyun Cheol. AU - Ahn, Joong Bae. PY - 2008/6/1. Y1 - 2008/6/1. N2 - S-1 is a novel, oral fluoropyrimidine and a known radiosensitizer. We conducted a phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer. Our findings suggest that this new combination is feasible and well tolerable.. AB - S-1 is a novel, oral fluoropyrimidine and a known radiosensitizer. We conducted a phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer. Our findings suggest ...
The likelihood of a tumor recurrence in patients with T3-4N0-1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected specimens are seen in only a minority (28-38%) of patients following chemoradiotherapy, we designed the INCREASE trial (EudraCT-Number: 2019-003454-83; Netherlands Trial Register number: NL8435) to assess if pCR rates could be further improved by adding short course immunotherapy to induction chemoradiotherapy. Translational studies will correlate changes in loco-regional and systemic immune status with patterns of recurrence. This single-arm, prospective phase II trial will enroll 29 patients with either resectable, or borderline resectable, T3-4N0-1 NSCLC. The protocol was approved by the institutional ethics committee. Study enrollment commenced in February 2020. On day 1 of guideline-recommended concurrent chemoradiotherapy (CRT), ipilimumab (IPI, 1 mg/kg IV) and nivolumab
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung ...
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung ...
Objectives: The main aims of study were to compare toxicity profile of IMRT with conventional Radiotherapy (2D RT) in head and neck cancer. Methods: The Study was a prospective one in which we included Eligible patients known case of head and neck cancer like oral cavity, nasopharaynx, oropharaynx, and hypopharyanx to received either definitive chemoradiation alone or adjuvant. Eligible patients in conventional group randomized to receive radiotherapy with parallel opposed lateral fields and one direct anterior lower neck. In IMRT group patients received either 7 fields or 5 fields or parotid sparing radiation. Patients Toxicity pattern (grades of mucositis, skin reaction, xerostomia, odynophagia) of both groups was noted down. Toxicity of Radio-Therapy (RT) developing within 90 days and more than 90 days from the beginning of RT assessed according to Radiation Therapy Oncology Group (RTOG) and European Organization for the Research and Treatment of Cancer (EORTC) criteria. Results: A total of ...
TY - JOUR. T1 - Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer. AU - Nitori, Nobuhiro. AU - Kato, Yutaro. AU - Kato, Ayu. AU - Deguchi, Tomoaki. AU - Okada, Akihiro. AU - Kojima, Masayuki. AU - Kuroda, Junko. AU - Kadomura, Tomohisa. AU - Kubota, Eisuke. AU - Origuchi, Nobuto. AU - Fujisaki, Masato. AU - Kitajima, Masaki. PY - 2011/11/1. Y1 - 2011/11/1. N2 - We report a case of anal cancer in a 58-year-old woman who complained of narrow, bloody stools and anal pain. Physical examination revealed anal stenosis associated with a circular mass arising in the anal canal. Histological examination of biopsy specimens confirmed a diagnosis of moderately differentiated squamous cell carcinoma. Enhanced computed tomography revealed anal cancer invading the levator ani and the vagina, with lymph-node, multiple hepatic, and pulmonary metastases. The patient received two cycle of chemoradiotherapy with S-1 plus low-dose cisplatin with ...
BackgroundTo evaluate the value of pretreatment inflammatory-nutritional biomarkers in predicting responses to neoadjuvant chemoradiotherapy (nCRT) and survival in patients with locally advanced rectal cancer (LARC).MethodsPatients with LARC who underwent nCRT and subsequent surgery between October 2012 and December 2019 were considered for inclusion. Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), and prognostic nutritional index (PNI) were calculated from according to routine laboratory data within 1 week prior to nCRT. The correlations between baseline inflammatory-nutritional biomarkers and responses were analyzed using Chi-square test or Fishers exact test, and multivariate logistic regression analysis was performed to identify the independent predictors of pathological responses to nCRT. Univariate and multivariate Cox proportional hazard models were used to assess the correlations of predictors with disease-free survival (DFS) and
PURPOSE: The purpose of this study was to combine gene expression profiles and clinical factors to provide a better prediction model of local control after chemoradiotherapy for advanced head and neck cancer. MATERIAL AND METHODS: Gene expression data were available for a series of 92 advanced stage head and neck cancer patients treated with primary chemoradiotherapy. The effect of the Chung high-risk and Slebos HPV expression profiles on local control was analyzed in a model with age at diagnosis, gender, tumor site, tumor volume, T-stage and N-stage and HPV profile status. RESULTS: Among 75 patients included in the study, the only factors significantly predicting local control were tumor site (oral cavity vs. Pharynx, hazard ratio 4.2 [95% CI 1.4-12.5]), Chung gene expression status (high vs. Low risk profile, hazard ratio 4.4 [95% CI 1.5-13.3]) and HPV profile (negative vs. Positive profile, hazard ratio 6.2 [95% CI 1.7-22.5]). CONCLUSIONS: Chung high-risk expression profile and a negative ...
The researchers identified 6 eligible randomized controlled trials. The team found that chemoradiotherapy plus surgery, compared with surgery alone, significantly reduced the 3 year mortality rate (odds ratio 0.53). They also found that preoperative chemoradiotherapy downstaged the tumor. However, the risk for postoperative mortality was higher in the chemoradiotherapy plus surgery group (odds ratio 2.10). Dr Fiorica and colleagues concluded, In patients with resectable esophageal cancer, chemoradiotherapy plus surgery significantly reduces 3 year mortality compared with surgery alone . However, postoperative mortality was significantly increased by neoadjuvant chemoradiotherapy . Further large scale multicenter randomized controlled trials may prove useful to substantiate the benefit on overall survival . ...
The present study contains novel findings to support the concept of immunogenic cell death induced by chemoradiotherapy in patients with ESCC. First, tumor antigen-specific T-cell responses were confirmed in 6 (38%) of 16 patients with ESCC following chemoradiotherapy. Second, the serum level of HMGB1 following chemoradiation in the patients with antigen-specific T-cell responses was significantly elevated in comparison to that in the patients without antigen-specific T-cell responses. Third, upregulation of HMGB1 within tumor microenvironments was significantly related to preoperative chemoradiotherapy and the degree of HMGB1 positively correlated with patients survival. Fourth, both irradiation and chemodrugs could induce upregulation of HMGB1 and calreticulin on ESCC cell lines in vitro. Finally, HMGB1 was able to induce maturation of DCs in an in vitro culture system.. In general, chemoradiotherapy is thought to induce an immunosuppressive state in both T-cell and natural killer-cell ...
From a clinical perspective, although T2 stage cancer is not an indication for CCRT in the National Comprehensive Cancer Networkguidelines [2-6], some patients with T2 stage cancers undergo CCRT. CCRT was associated with a high pCR rate in some studies, including in our study. Therefore, CCRT may be suitable for selected patients who require analsparing procedures. A major factor in selecting CCRT for T2 stage cancer is precise T staging using appropriate imaging modalities, and this attempts to predict pCR. A long interval between finishing CCRT and surgery was a significant predictive factor in the multivariate analysis in our study. Thus, the timing of surgery is important. Some studies reported the interval between CCRT and surgery [25,26], in which the interval ranged from 4 to 8 weeks. Based on the findings of these studies, all patients could undergo complete resection without an increased rate of postoperative complications. According to these results, an interval of 4-8 weeks from ...
Fingerprint Dive into the research topics of Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Together they form a unique fingerprint. ...
Surgery and chemoradiotherapy. The types of operations and chemoradiotherapy are set out in Table 4. Type of operation and chemoradiotherapy were significantly associated (p,0.001). Most of the patients presented with advanced disease that was not resectable, and 72.5% (n=95) did not undergo surgery with curative intent owing to advanced disease. Only 1 patient (0.1%) had neoadjuvant chemotherapy, 21 (16.0%) had adjuvant chemotherapy, and 17 (13%) had radiotherapy.. Discussion. Our data show some interesting local variations. There appears to be a relatively high burden of GC in the Indian population, as evidenced by the observation that Indian patients made up 48.1% of the GC patients in our series yet only comprise 7.4% of the population of KZN.[4] This observation may simply reflect referral bias, and ongoing audit is required to see whether this apparent racial difference is a real phenomenon. There was a slight male preponderance, with 55.0% males and 45.0% females. There were no ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Noordman, B.J.; Spaander, M.C.W.; Valkema, R.; Wijnhoven, B.P.; Berge Henegouwen, M.I. van; Shapiro, J.; Siersema, P.D.; Janssen, M.J.R.; Post, R.S. van der; Radema, S.A.; Rosman, C. ; Rütten, H.; Lanschot, J.J. van; Steyerberg, E.W. ...
Adjuvant carboplatin and paclitaxel after standard cisplatin-based chemoradiation did not demonstrate improved overall survival or progression-free survival in patients with locally advanced cervical cancer.
There is paucity of information regarding a late toxic reaction after chemoradiation for locally advanced cervical cancer. We discuss this problem with special consideration to total vaginal necrosis (TVN), an underreported severe late complication of chemoradiation ...
Rectal cancer management is becoming increasingly complex. There is increasing recognition of the potential to avoid routine chemoradiotherapy, as excellent results can be achieved with a more selective approach.
All the cancer patients should receive a full course of chemotherapy rather than chemoradiotherapy following surgical treatment for pancreatic cancer.
(HealthDay) -- For most patients with locally advanced pancreatic carcinoma (LAPC), induction with a combination of gemcitabine and oxaliplatin (GEMOX) followed by chemoradiotherapy (CRT) is feasible, resulting in clinical ...
Poster: ECR 2015 / B-0665 / Role of DWI in cervical cancer for prediction and monitoring of chemoradiotherapy response by: P. Kala, D. V. Bhargavi, R. Avantsa, G. Narayan; Bangalore/IN
Treatment involves surgical resection and possible chemoradiotherapy. Although penile sparing is the goal, total penectomy may ...
O'Rourke N, Roqué I, Figuls M, Farré Bernadó N, Macbeth F (June 2010). "Concurrent chemoradiotherapy in non-small cell lung ... In addition, exercise training can benefit people with NSCLC who have received radiotherapy, chemotherapy, chemoradiotherapy, ...
Evidence suggests chemoradiotherapy may increase overall survival and reduce the risk of disease recurrence compared to ... Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC) (January 2010). "Reducing uncertainties about the ... "Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer ... effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis". The Cochrane Database of Systematic ...
sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the question". Translational Lung Cancer Research. 5 (2 ... the current standard treatment for fit patients is concurrent chemoradiotherapy. Concurrent chemoradiotherapy is a combination ... Concurrent chemoradiotherapy also remains the mainstay treatment for patients aged 70 years or more and showed a survival ... The time between the start and the end of chemoradiotherapy is a predicator of survival in limited stage small cell lung cancer ...
The role of combined chemoradiotherapy in this setting is unclear. However, if the tumor tissue margins are positive, ... "Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar ...
This combination approach may be substituted with chemoradiotherapy alone in some. Hysterectomy and bilateral oophorectomy is ...
"Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas". Journal of Neuro-Oncology. 90 ( ...
In elderly people with newly diagnosed glioblastoma who are reasonably fit, concurrent and adjuvant chemoradiotherapy gives the ... December 2008). "Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas". Journal of ... signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in ...
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck ClinicalTrials. ... chemo)radiotherapy in head and neck cancer". Head Neck. 27 (3): 175-81. CiteSeerX 10.1.1.469.8139. doi:10.1002/hed.20130. PMID ... "Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma". International Journal of Radiation ... control based on pretreatment nodal size in squamous cell carcinoma of the head and neck treated with chemoradiotherapy: a ...
For locally advanced rectal cancer, neoadjuvant chemoradiotherapy has become the standard treatment. Additionally, when surgery ... 2016). "A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer". International Journal of Biological ... chemoradiotherapy can increase acute treatment-related toxicity, and has not been shown to improve survival rates compared to ...
January 2007). "HSP60 may predict good pathological response to neoadjuvant chemoradiotherapy in bladder cancer". Jpn. J. Clin ...
Chemoradiotherapy is a standard treatment for advanced esophageal squamous cell carcinoma (ESCC). Reduced PINX1 expression did ...
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. „J Clin Oncol". ... A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. „Ann Surg Oncol". 8 (6), s. 519-524, Jul 2001. ... Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced ...
"Olfactory neuroblastoma with epithelial and endocrine differentiation transformed into ganglioneuroma after chemoradiotherapy ...
"ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy". J. Cancer Res. ...
Notably, males who have undergone chemo/radiotherapy prepubertally may benefit from in vitro spermatogenesis. These people did ...
MacDonald (6 September 2001). "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or ...
"Prognostic Significance of Two Dimensional AgNOR Evaluation in Local Advanced Rectal Cancer Treated with Chemoradiotherapy". ...
Bishop, S; Reed, WM (December 2015). "The provision of enteral nutritional support during definitive chemoradiotherapy in head ...
Louis in JAMA Oncology, assessing whether proton therapy in the setting of concurrent chemoradiotherapy is associated with ... Baumann BC (2020). "Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally ... The study included 1483 adult patients with nonmetastatic, locally advanced cancer treated with concurrent chemoradiotherapy ... with curative intent and concluded that 'proton chemoradiotherapy was associated with significantly reduced acute adverse ...
"Hypermethylation of RAD51L3 and XRCC2 genes to predict late toxicity in chemoradiotherapy-treated cervical cancer patients". ...
Whilst, evidence is uncertain on whether there are long term neurocognitive side effects associated with chemoradiotherapy. ...
Results of preoperative chemoradiotherapy for patients with advanced cancer of the nasal cavity and paranasal sinuses. Acta Oto ...
"A Specific miRNA Signature Correlates with Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced ...
... usually definitive combination chemoradiotherapy. APRs involves removal of the anus, the rectum and part of the sigmoid colon ...
Chemo) Radiotherapy: Impact of Service-Delivery Model and Patient Factors". Dysphagia. 32 (2): 279-292. doi:10.1007/s00455-016- ... chemo)radiotherapy". Oral Oncology. 54: 47-53. doi:10.1016/j.oraloncology.2016.01.004. PMID 26803342. Wall, Laurelie R; Ward, ... Chemo)Radiotherapy". Dysphagia. 34 (5): 627-639. doi:10.1007/s00455-018-9960-1. PMID 30515560. S2CID 54444651. Burns, Clare L ... chemo)radiotherapy". Supportive Care in Cancer. 24 (3): 1227-1234. doi:10.1007/s00520-015-2912-5. PMID 26304158. S2CID 1137901 ...
Larger doses of radiation are used in modern chemoradiotherapy protocols versus the original Nigro protocol radiotherapy dose. ...
March 2013). "Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent ... "Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they ... "HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of ... "An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients ...
"Effect of injection of brucea javanica oil emulsion plus chemoradiotherapy for lung cancer: a review of clinical evidence". J ...
... immunotherapy and combined treatment modalities such as chemo-radiotherapy. Starting in the mid-1990s, the emphasis in clinical ...
Medical Definition of Chemoradiotherapy Neuner G, Patel A, Suntharalingam M (2009). "Chemoradiotherapy for esophageal cancer". ... Chemoradiotherapy (CRT, CRTx, CT-RT) is the combination of chemotherapy and radiotherapy to treat cancer. Synonyms include ... Chemoradiotherapy as neoadjuvant therapy before surgery has been shown to be effective in esophageal cancer. ... Chemotherapy and chemoradiotherapy for rectal cancer. (Macmillan/NHS) v t e. ...
... such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB ... Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma. *Tae Hyun Kim. ORCID: orcid.org/0000-0001-8413-33851. ... Kim, T.H., Woo, S.M., Lee, W.J. et al. Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma. Sci Rep 9, ... Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 29, 4627-4632, ...
Neoadjuvant chemoradiotherapy was connected with a little higher mortality after surgery. But it did not increase the incidence ... Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs ... Patients With Resectable Esophageal Adenocarcinoma Benefit From Neoadjuvant Chemoradiotherapy. by Sam Savage ... Compared with patients treated by surgery alone, patients receiving neoadjuvant chemoradiotherapy more likely obtained complete ...
Chemoradiotherapy for Advanced Esophageal Cancer. The safety and scientific validity of this study is the responsibility of the ... A Phase 2 Study of Palliative Chemo-Radiotherapy With Carbo-Taxol in Non-Curative Cancer of the Esophagus. ... and who have no contra-indications to chemo-radiotherapy will be offered Carboplatin (AUC 2) and paclitaxel (50 mg/m2) ...
Experimental: Valporoic acid + chemoradiotherapy Drug: Valproic acid Valproic acid given concurrent with chemoradiotherapy for ... Valproic Acid With Chemoradiotherapy for Pancreatic Cancer. The safety and scientific validity of this study is the ... This is non-randomized phase 2 study to evaluate toxicity and efficacy of valproic acid (VA) with concurrent chemoradiotherapy ... Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Gemcitabine for Unresectable Locally Advanced Pancreatic ...
Chemoradiotherapy (CRT) represents a standard treatment for many human cancers, frequently combined with radical surgical ... Keywords: STAT3; cancer; radiotherapy; chemoradiotherapy; chemoradiotherapy-resistance; chemoradiotherapy-sensitization; ... molecular target STAT3; cancer; radiotherapy; chemoradiotherapy; chemoradiotherapy-resistance; chemoradiotherapy-sensitization ... STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. Melanie Spitzner 1,* , Reinhard Ebner 2. ...
Postoperative Chemoradiotherapy Regimens. Uses of the following postoperative chemoradiotherapy regimens include cancers of the ... Neoadjuvant Chemoradiotherapy Regimens. Preferred regimens. A higher level of evidence supports use of the following regimens; ... Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31. 366(22):2074-84. [Medline]. [ ... Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N ...
Chemoradiotherapy: Concurrent Uses, Efficacy and Impact on Prognosis. Daniel Sullivan (Editor). Series: Cancer Etiology, ... Chemoradiotherapy is the use of both chemotherapy and radiotherapy for the treatment of cancer. This book discusses its ... Home / Shop / Books / Medicine and Health / Chemoradiotherapy: Concurrent Uses, Efficacy and Impact on Prognosis. ...
... definitive chemoradiotherapy, postoperative chemoradiotherapy, and metastatic disease. Category 1 and 2A regimens are indicated ... Neoadjuvant Chemoradiotherapy, Resectable Disease. Neoadjuvant chemoradiotherapy appears to be associated with better survival ... Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; May 31. 366(22):2074-84. [Full Text]. ... Postoperative Chemoradiotherapy for Adenocarcinomas. Surgery can be the initial treatment of choice for patients with ...
FertiPROTEKT Network for Fertility Preservation Techniques before Chemo- & Radiotherapy. Journal f r Reproduktionsmedizin und ...
Concurrent chemoradiotherapy with proton radiation can reduce short-term side effects that caused unplanned hospitalizations, ... Concurrent Chemoradiotherapy With Proton Radiation Reduces Short-Term Side Effects. Concurrent chemoradiotherapy with proton ... but limited data are available comparing results of proton chemoradiotherapy with chemoradiotherapy delivered with photon ... Proton chemoradiotherapy was associated with a significantly lower relative risk of 90-day side effects of at least grade 3, 90 ...
ConclusionThe vast divergence in prognosis between young and old GBM patients is largely caused by choice of treatment rather than age ‐related tumor genomic characteristics. Postoperative standard radio‐ and chemotherapy provide strong benefits to primary glioblastoma patients of all ages....
Chemoradiotherapy for cervical cancer: results of a meta-analysis. Women with cervical cancer that is too big to be removed by ... Women who received chemoradiotherapy were also less likely to have the cancer come back or spread to other parts of the body. ... This is called chemoradiotherapy (or chemoradiation). This review brought together 18 randomised controlled trials (RCTs) that ... Chemoradiotherapy helped all women, even those with bigger tumours, or tumours that had spread more. Also, the different drugs ...
Background Clinical trials report improved overall survival following neoadjuvant chemoradiotherapy in patients undergoing ... Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-84.CrossRefPubMedGoogle ... Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results ... MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann Thorac Surg. 2012;94(4): ...
... is potentially the only treatment available that can offer a chance of long-term survival when definitive chemoradiotherapy ( ... Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a ... Hironaka S, Ohtsu A, Boku N et al (2003) Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in ... Tachimori Y, Kanamori N, Uemura N et al (2009) Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous ...
Twenty-three NPC patients with diplopia after concurrent chemoradiotherapy were enrolled in this study. Unilateral cranial VI ... We retrospectively reviewed the medical records of NPC patients with new onset diplopia after concurrent chemoradiotherapy from ... New Onset Diplopia in Patients with Nasopharyngeal Carcinoma following Concurrent Chemoradiotherapy: Clinical Features and ... and radiotherapy or concurrent chemoradiotherapy (CCRT) is the mainstay treatment for this disease. The proximity of ...
Mucinous Adenocarcinoma Arising in Chronic Perianal Fistula: Good Results with Neoadjuvant Chemoradiotherapy Followed by ... The patient underwent a laparoscopic colostomy followed by neoadjuvant chemoradiotherapy and then laparoscopic abdominoperineal ...
A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas. Trial ... A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas ... Assess treatment feasibility of neoadjuvant temozolomide-based proton chemoradiotherapy for high-risk soft tissue sarcoma ...
France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic ... Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer. May 03, 2016. In a study appearing in the May 3 ... With a median follow-up of 36.7 months, the researchers found no survival benefit of chemoradiotherapy compared with ... In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of erlotinib is unknown ...
and safety of weekly cisplatin / liposome paclitaxel concurrent chemoradiotherapy and. radiotherapy alone in the treatment of ...
Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells Dig Dis Sci. 2011 Mar;56(3):741-50. ...
Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma S. Setua, M. Ouberai, S. G. Piccirillo, C ... We report the first successful chemo-radiotherapy on patient derived treatment resistant GBM cells using a cisplatin-tethered ...
Chemoradiotherapy Produces CRs in Inoperable Head and Neck Cancer. @media screen and (max-width: 468px) { .video-detail .doc- ...
Concurrent chemoradiotherapy for cervical carcinoma develops rapidly and has become a common and standard therapy in recent ... Chemoradiotherapy* / adverse effects. Chemotherapy, Adjuvant. Cisplatin / adverse effects, therapeutic use. Diarrhea / ... CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and ... BACKGROUND AND OBJECTIVE: Concurrent chemoradiotherapy for cervical carcinoma develops rapidly and has become a common and ...
There have been few reports regarding the clinical outcomes of definitive chemoradiotherapy (dCRT) for EsoNEC. The purpose of ... Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.. 07:00 EST 3rd ... A multimodality approach using concurrent chemoradiotherapy (CRT) followed by esophagectomy has been the standard treatment in ... Histogram analysis of DCE-MRI for chemoradiotherapy response evaluation in locally advanced esophageal squamous cell carcinoma. ...
Although many trials have shown the efficacy of preoperative chemoradiotherapy (CRT) or postoperative CRT compared with surgery ... Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced ...
Background: Changes in salivary flow rate were studied in head and neck (H and N) cancer patients who, after receiving moderately accelerated radiotherapy (RT) and concurrent chemotherapy (CT), were free of disease at 1 year. Materials and Methods: B
... September 10, 2012. No Comments ... Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine. 2012; 366: 2074-2084. ... Preoperative chemoradiotherapy doubled median overall survival among patients with esophageal or esophagogastric junction ... The results indicated that preoperative chemoradiotherapy reduced the risk of death by 34 percent. Median overall survival was ...
Correction to: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced ... Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal ... Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal ... Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal ...
  • This is non-randomized phase 2 study to evaluate toxicity and efficacy of valproic acid (VA) with concurrent chemoradiotherapy (CCRT) containing weekly gemcitabine in patients with unresectable locally advanced pancreatic cancer (ULAPC). (clinicaltrials.gov)
  • Concurrent chemoradiotherapy with proton radiation can reduce short-term side effects that caused unplanned hospitalizations, with similar disease-free and overall survival, compared with photon radiation. (curetoday.com)
  • Concurrent chemoradiotherapy with proton radiation can reduce short-term side effects that caused unplanned hospitalizations, with similar disease-free and overall survival, compared with photon radiation, according to study results published in JAMA Oncology . (curetoday.com)
  • These findings suggest that, in adults with locally advanced cancer, proton therapy with concurrent chemoradiotherapy may significantly reduce severe adverse events compared with photon therapy, with comparable oncologic outcomes," the researchers wrote. (curetoday.com)
  • Proton therapy as part of concurrent chemoradiotherapy may be able to reduce treatment toxicity, but limited data are available comparing results of proton chemoradiotherapy with chemoradiotherapy delivered with photon therapy, and proton therapy remains unproven in this setting," the researchers wrote. (curetoday.com)
  • To investigate the clinical features and etiology of nasopharyngeal carcinoma (NPC) patients with new onset diplopia after concurrent chemoradiotherapy. (hindawi.com)
  • We retrospectively reviewed the medical records of NPC patients with new onset diplopia after concurrent chemoradiotherapy from 1998 to 2012 in a cancer center. (hindawi.com)
  • Twenty-three NPC patients with diplopia after concurrent chemoradiotherapy were enrolled in this study. (hindawi.com)
  • Nasopharyngeal carcinoma (NPC) is an epithelial malignancy with high prevalence in Southeast Asia, and radiotherapy or concurrent chemoradiotherapy (CCRT) is the mainstay treatment for this disease. (hindawi.com)
  • In this study ,we replace the conventional dose chemotherapy with weekly cisplatin or lipsome paclitaxel , to compare the efficiency and safety of weekly cisplatin / liposome paclitaxel concurrent chemoradiotherapy and radiotherapy alone in the treatment of cervical cancer in elderly patients. (knowcancer.com)
  • Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer. (biomedsearch.com)
  • BACKGROUND AND OBJECTIVE: Concurrent chemoradiotherapy for cervical carcinoma develops rapidly and has become a common and standard therapy in recent years. (biomedsearch.com)
  • This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment compliance of the patients with advanced cervical squamous cell carcinoma. (biomedsearch.com)
  • METHODS: A total of 156 patients with stage IIa-IIIb cervical squamous cell carcinoma were randomly divided into the concurrent chemoradiotherapy group (experimental group) and radiotherapy group (control group). (biomedsearch.com)
  • CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and long-term survival and local control rates of patients, improve the quality of life, and the toxicity can be tolerated. (biomedsearch.com)
  • A multimodality approach using concurrent chemoradiotherapy (CRT) followed by esophagectomy has been the standard treatment in patients with locally advanced esophageal squamous cell carcinoma (ESCC). (bioportfolio.com)
  • This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell c. (bioportfolio.com)
  • Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propens. (nih.gov)
  • Correction to: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis. (nih.gov)
  • Promising efficacy and manageable toxicity of docetaxel-based concurrent chemoradiotherapy (CCRT) were reported in head and neck cancer. (nih.gov)
  • Concurrent chemoradiotherapy has been proven efficaciously superior than sequential therapy and is the current standard of care for a number of malignancies, including rectal, head and neck, lung, and esophageal cancers. (aacrjournals.org)
  • Therefore, we have developed a multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiotherapy. (aacrjournals.org)
  • In summary, we have developed a novel targeted nanoparticle platform that can carry both chemotherapeutics and metal radioisotopes, making nanoparticle delivery of concurrent chemoradiotherapy possible. (aacrjournals.org)
  • Preoperative chemoradiotherapy (five courses of carboplatin and paclitaxel, with 41.4Gy of concurrent radiotherapy) is safe and leads to a significant increase in overall survival among patients with adenocarcinoma or squamous-cell carcinoma of the esophagus or esophagogastric junction," the authors write. (empr.com)
  • Background:Although concurrent chemoradiotherapy is effective for improving disease-free survival and overall survival in patients with locally advanced nasopharyngeal carcinoma. (clinicaltrials.gov)
  • Neoadjuvant concurrent chemoradiotherapy (CCRT) is an increasingly common therapeutic strategy for locally advanced rectal cancer, but stratification of risk and final outcomes remain a major challenge. (nih.gov)
  • Nasopharyngeal carcinoma (NPC) patients receiving concurrent chemoradiotherapy (CCRT) frequently develop low skeletal muscle mass (SMM), but, little is known about the impacts of low SMM on health-related quality of life (QOL). (frontiersin.org)
  • CHICAGO - A phase 3 noninferiority study has found that in patients with nonoperable locally advanced squamous cell cancer of the head and neck, concurrent chemoradiotherapy remains the standard treatment, according to results presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting. (oncologynurseadvisor.com)
  • Concurrent chemoradiotherapy (CCRT) has now become the standard of treatments for advanced rectal cancer before surgery. (medsci.org)
  • T3, T4 and node positive diseases), concurrent chemoradiotherapy (CCRT) followed by tumor resection is considered the standard of treatment nowadays. (medsci.org)
  • Most people are diagnosed with esophageal cancer present with locally advanced disease, to which concurrent chemoradiotherapy has emerged as a standard treatment [ 2 ]. (pubmedcentralcanada.ca)
  • In the Radiation Therapy Oncology Group 85-01 randomized trial, definitive chemoradiotherapy using 5-fluororuracil, cis -diammine-dichloroplatinum (cisplatin), and concurrent radiation (50 Gy) has achieved a 26% 5-year survival ( 3 ), similar to surgery alone ( 4 , 5 ). (aacrjournals.org)
  • Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer. (pubfacts.com)
  • Fifty two patients with locally recurrent stage III NSCLC after concurrent chemoradiotherapy were randomly divided into two groups ( n = 26). (biomedcentral.com)
  • Concurrent chemoradiotherapy (CCRT) was delivered to all cases. (alliedacademies.org)
  • Pelvic concurrent chemoradiotherapy (CCRT) is recommended for LACC according to NCCN Guideline [ 2 , 3 ]. (alliedacademies.org)
  • Preoperative chemoradiotherapy for esophageal or junctional cancer. (springer.com)
  • Although many trials have shown the efficacy of preoperative chemoradiotherapy (CRT) or postoperative CRT compared with surgery alone, the optimal sequence of radiotherapy and surgery is unclear. (nih.gov)
  • Preoperative chemoradiotherapy doubled median overall survival among patients with esophageal or esophagogastric junction cancer compared to surgery alone, according to the results of a phase 3 study published in the New England Journal of Medicine . (cancerconnect.com)
  • The results indicated that preoperative chemoradiotherapy reduced the risk of death by 34 percent. (cancerconnect.com)
  • The researchers concluded that preoperative chemoradiotherapy is safe and improved survival among patients with potentially curable esophageal or esophagogastric-junction cancer. (cancerconnect.com)
  • The current study tested the hypothesis that the clinical outcome of patients with localized esophageal carcinoma after preoperative chemoradiotherapy (CTRT) depends on histology. (wiley.com)
  • This study was done to determine the impact of weight loss during preoperative chemoradiotherapy (CRT) on the survival outcome of patients with locally advanced rectal cancer (LARC). (urotoday.com)
  • But, these preliminary results of PREOPANC suggest a benefit of preoperative chemoradiotherapy over immediate surgery followed by adjuvant chemotherapy," said lead study author Geertjan Van Tienhoven, MD, PhD, of the Department of Radiation Oncology, Academic Medical Center in Amsterdam, Netherlands. (onclive.com)
  • Surgery with or without preoperative chemoradiotherapy is generally done for resectable cases and chemoradiotherapy is used for unresectable cases or resectable cases where patients do not wish to have surgery. (aacrjournals.org)
  • Preoperative chemoradiotherapy (CRT) has been used as a standard treatment in patients with locally advanced rectal cancer (LARC) because of increased local control, organ preservation and less toxicity [ 1 ]. (jcancer.org)
  • To examine toxicity and outcomes for patients treated with preoperative chemoradiotherapy (CRT) for gastric cancer. (biomedcentral.com)
  • Histological subgroup analysis indicated that esophageal squamous cell carcinoma did not benefit from neoadjuvant chemoradiotherapy. (redorbit.com)
  • Salvage esophagectomy is potentially the only treatment available that can offer a chance of long-term survival when definitive chemoradiotherapy (CRT) fails to achieve local control for patients with esophageal squamous cell carcinoma (ESCC). (springer.com)
  • Takeuchi H, Ozawa S, Ando N et al (2003) Cell cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. (springer.com)
  • Hironaka S, Ohtsu A, Boku N et al (2003) Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3) N(any) M(0) squamous cell carcinoma of the esophagus. (springer.com)
  • Tachimori Y, Kanamori N, Uemura N et al (2009) Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. (springer.com)
  • Tumor Remission and tumor-infiltrating lymphocytes during chemoradiotherapy: predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma. (bioportfolio.com)
  • Clinical tools are unavailable for accurately predicting the pathological responses to chemoradiotherapy (CRT) of patients with esophageal squamous cell carcinoma (ESCC) before surgery. (bioportfolio.com)
  • Histogram analysis of DCE-MRI for chemoradiotherapy response evaluation in locally advanced esophageal squamous cell carcinoma. (bioportfolio.com)
  • Whether nutritional assessment and management improves clinical outcomes in patients with clinical T1N0M0 esophageal squamous cell carcinoma (ESCC) who undergo chemoradiotherapy remains to be demonstrated. (dovepress.com)
  • Peter van Hagen, MCCM, from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues investigated the role of neoadjuvant chemoradiotherapy in the treatment of 366 patients with resectable esophageal or esophagogastric-junction cancer (275 with adenocarcinoma, 84 with squamous-cell carcinoma, and seven with large-cell undifferentiated carcinoma). (empr.com)
  • The effects of replacing cisplatin (CDDP) with cis -diammineglycolatoplatinum (nedaplatin, NDP), a second-generation platinum complex, on the pharmacokinetics of 5-fluorouracil (5-FU) were investigated in Japanese patients with esophageal squamous cell carcinoma, who were treated with a definitive 5-FU/CDDP-based chemoradiotherapy. (medsci.org)
  • Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma. (snfge.org)
  • To assess the efficacy of endoscopic head and neck surgery (transoral robotic surgery or transoral laser microsurgery) for small-volume, primary (T1-2, N0-2) oropharyngeal squamous cell carcinoma (OPSCC) in comparison to radiotherapy/chemoradiotherapy. (altmetric.com)
  • Forty-seven patients with advanced larynx/hypopharynx, nasopharynx or oropharynx/oral cavity cancer were recorded before, and 10 weeks after concomitant chemoradiotherapy (CCRT), to investigate the effect of the tumor versus the effects of treatment. (uva.nl)
  • Cisplatin-based chemoradiotherapy is a standard-of-care for locally advanced head and neck cancer but is frequently ineffective. (aacrjournals.org)
  • In a Chinese phase III trial reported in The New England Journal of Medicine , Yuan Zhang, MD, PhD , and colleagues found that the addition of gemcitabine/cisplatin induction chemotherapy to standard platinum-based chemoradiotherapy improved recurrence-free survival vs chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. (ascopost.com)
  • Patients were randomly assigned between December 2013 and September 2016 to receive gemcitabine at 1 g/m 2 on days 1 and 8 and cisplatin at 80 mg/m 2 on day 1 every 3 weeks for three cycles plus standard chemoradiotherapy (n = 242) or standard chemoradiotherapy alone (n = 238). (ascopost.com)
  • Chemoradiotherapy consisted of 100 mg/m 2 of cisplatin every 3 weeks on days 1, 22, and 43, plus intensity-modulated radiotherapy. (ascopost.com)
  • This study suggests that concomitant chemoradiotherapy with 45 Gy to the whole pelvis concomitant with cisplatin chemotherapy and four fractions of 6 Gy to point ''A'' with HDR brachytherapy is an effective and tolerable fractionation schedule in the treatment of Stages IB2 and II cervix cancer. (ajol.info)
  • Standard chemoradiotherapy (CRT) using cisplatin (CDDP) and 5-fluorouracil (5-FU) is an optional treatment for patients with stage II-III esophageal cancer. (pubfacts.com)
  • Pre-operative chemoradiotherapy using a 5-fluorouracil (5-FU)/cisplatin backbone is widely used to improve surgical outcomes in locoregional oesophageal cancer patients, despite a non-negligible failure rate. (springermedizin.de)
  • We evaluated intensification of this approach to improve patient outcomes by adding cetuximab to induction 5-FU/cisplatin/docetaxel (TPF) and to chemoradiotherapy in a phase II study. (springermedizin.de)
  • To evaluate the benefit of adjuvant treatments, such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB) cancer patients, 151 patients were analyzed: 98 (64.9%) patients received adjuvant treatment with CRT (n = 59, 39.1%) or CTx (n = 39, 25.8%), and the remaining 53 (35.1%) did not (No-AT). (nature.com)
  • The patient underwent a laparoscopic colostomy followed by neoadjuvant chemoradiotherapy and then laparoscopic abdominoperineal resection followed by adjuvant therapy. (hindawi.com)
  • As reported in The Lancet Oncology by de Boer et al, the phase III PORTEC-3 trial has shown no significant improvement in 5-year overall survival with adjuvant chemoradiotherapy vs radiotherapy alone in women with high-risk endometrial cancer. (ascopost.com)
  • Adjuvant chemoradiotherapy, however, was associated with significantly improved failure-free survival. (ascopost.com)
  • Many recurrences in esophageal cancer after neo-adjuvant chemoradiotherapy and surgery occur at distant locations from the surgical site. (termedia.pl)
  • Role of chemoradiotherapy in oesophageal cancer -- adjuvant and neoadjuvant therapy. (semanticscholar.org)
  • Chemoradiotherapy (CRT), either given before surgical resection as neoadjuvant therapy or after resection as adjuvant therapy, has been postulated to improve these outcomes. (semanticscholar.org)
  • Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients. (deepdyve.com)
  • Factors associated with advantage, postoperative chemoradiotherapy (CRT) has adjuvant CRT included age younger than 75 years at can- been a care standard for US patients in whom gastric cer diagnosis and stage II or stage III cancer. (deepdyve.com)
  • The intervention was transoral, minimally invasive surgery with or without adjuvant radiotherapy or adjuvant chemoradiotherapy. (altmetric.com)
  • Chemoradiotherapy (CRT) represents a standard treatment for many human cancers, frequently combined with radical surgical resection. (mdpi.com)
  • HealthDay News) - For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, according to a study published in the May 31 issue of the New England Journal of Medicine . (empr.com)
  • Prior retrospective analyses offer differing conclusions on the benefit of surgical resection after chemoradiotherapy (CRT) in these patients. (jnccn.org)
  • Treatment involves surgical resection and possible chemoradiotherapy. (wikipedia.org)
  • In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of erlotinib is unknown. (brightsurf.com)
  • To explore the efficacy of neoadjuvant (before surgery) chemoradiotherapy, researchers in the Netherlands conducted a Phase III clinical trial that included 366 patients with operable tumors. (cancerconnect.com)
  • This ongoing study is designed to assess the efficacy and safety of pmab in combination with radiotherapy (PRT) compared to chemoradiotherapy (CRT) as initial treatment of unresected, locally advanced SCCHN (ClinicalTrials.gov Identifier: NCT00547157). (linkos.cz)
  • We conducted a single-arm prospective study to confirm the efficacy and safety of selective chemoradiotherapy (CRT) based on findings from endoscopic resection (ER). (snfge.org)
  • We investigated the ability of miRNAs to predict outcomes after neoadjuvant chemoradiotherapy. (springer.com)
  • Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy. (bioportfolio.com)
  • There have been few reports regarding the clinical outcomes of definitive chemoradiotherapy (dCRT) for EsoNEC. (bioportfolio.com)
  • This study aimed to determine the nutritional status of such patients pre- and post-chemoradiotherapy and its clinical outcomes. (dovepress.com)
  • however, it is associated with a better prognosis.Until recently, first-line management of OPSCC involved chemoradiotherapy, as research had demonstrated comparable survival outcomes when compared with open surgery, with significantly decreased morbidity. (altmetric.com)
  • The reuslts showed neoadjuvant chemoradiotherapy significantly improved the overall survival compared with surgery alone. (redorbit.com)
  • Therefore, they compared the rate of severe 90-day side effects associated with unplanned hospitalizations or other side effects and similar disease-free and overall survival for patients treated with proton (391 patients), versus photon chemoradiotherapy (1,092 patients) in 1,483 patients with nonmetastatic, locally advanced cancer. (curetoday.com)
  • Clinical trials report improved overall survival following neoadjuvant chemoradiotherapy in patients undergoing surgery for esophageal adenocarcinoma, with a 10-15% survival improvement. (springer.com)
  • In a study appearing in the May 3 issue of JAMA , Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. (brightsurf.com)
  • With a median follow-up of 36.7 months, the researchers found no survival benefit of chemoradiotherapy compared with chemotherapy, with median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectively. (brightsurf.com)
  • Median overall survival was significantly longer in the group that received chemoradiotherapy-49.4 months, compared to 24 months in the group that received surgery alone. (cancerconnect.com)
  • The median overall survival was 49.4 and 24 months in the chemoradiotherapy-surgery and surgery-alone groups, respectively. (empr.com)
  • Chemoradiotherapy did not significantly improve 5-year overall survival but did improve 5-year failure-free survival. (ascopost.com)
  • Five-year overall survival was 81.8% in the chemoradiotherapy group vs 76.7% in the radiotherapy group (adjusted hazard ratio [HR] = 0.76, P = .11). (ascopost.com)
  • Findings from a recent study demonstrate that the PD-L1 inhibitor durvalumab demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared with placebo for patients with Stage III, unresectable non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy (CRT). (ecancer.org)
  • The investigators concluded, "Induction chemotherapy added to chemoradiotherapy significantly improved recurrence-free survival and overall survival as compared with chemoradiotherapy alone among patients with locoregionally advanced naso-pharyngeal carcinoma. (ascopost.com)
  • In the present study, microvessel factors, including hotspot MVD and TP/TA, TN/TA, and hypoxic ratios, in biopsy specimens from 51 patients with esophageal cancer treated with chemoradiotherapy were analyzed, and the relations between these factors and overall survival were assessed. (aacrjournals.org)
  • Manapov F, Eze C, Niyazi M, Roengvoraphoj O, Li M, Hegemann NS, Hildebrandt G, Fietkau R, Belka C. Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort. (jcancer.org)
  • This phase III randomized trial compared chemoradiotherapy (CTX/XRT) treatment to radiotherapy alone (XRT) for stage III and IV nasopharynx cancer. (oncolink.org)
  • In the open-label international trial, 660 eligible patients with high-risk disease from 103 sites in the United Kingdom, Australia, New Zealand, Italy, Canada, and France collaborating in the Gynaecological Cancer Intergroup were randomized between November 2006 and December 2013 to receive chemoradiotherapy (n = 330) or pelvic radiotherapy alone (n = 330). (ascopost.com)
  • Thus, pain control is an important problem in chemoradiotherapy for nasopharyngeal carcinoma.We performed to examine whether early induction of low-dose, opioid from moderate pain reduced total dose of Oxycodone during chemoradiotherapy, while improves the quality of life and reduce weight loss. (clinicaltrials.gov)
  • Meng L, Wei J, Ji R, Wang B, Xu X, Xin Y, Jiang X. Effect of Early Nutrition Intervention on Advanced Nasopharyngeal Carcinoma Patients Receiving Chemoradiotherapy. (jcancer.org)
  • Recently, a combination of neoadjuvant chemoradiotherapy followed by esophagectomy is the standard treatment for patients with esophageal cancer [5]. (termedia.pl)
  • A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. (springer.com)
  • Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. (springer.com)
  • What's more-complete resection with no tumor within 1 mm of the resection margins was achieved in 92 percent of patients in the chemoradiotherapy-surgery group versus 69 percent in the surgery group. (cancerconnect.com)
  • To investigate the capability of computed-tomography (CT) radiomic features to predict the therapeutic response of Esophageal Carcinoma (EC) to chemoradiotherapy (CRT). (pubmedcentralcanada.ca)
  • The results of the present study demonstrated that re-irradiation, with or without chemotherapy, for recurrent esophageal carcinoma after definitive chemoradiotherapy was tolerable and yielded reasonably satisfactory results. (pubfacts.com)
  • Neoadjuvant cetuximab/TPF followed by chemoradiotherapy in locoregional oesophageal carcinoma patients is feasible and offers a modest response rate in this trial. (springermedizin.de)
  • This pilot study is aimed to investigate the effect of neoadjuvant chemoradiotherapy on objectively measured in vivo muscle mitochondrial function and whole-body physical fitness. (soton.ac.uk)
  • Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. (springer.com)
  • Endoscopic biopsies from esophageal adenocarcinomas were obtained before neoadjuvant chemoradiotherapy and esophagectomy. (springer.com)
  • miRNA-ratio biomarkers identified using next generation sequencing can be used to predict disease free survival following neoadjuvant chemoradiotherapy and esophagectomy in patients with esophageal adenocarcinoma. (springer.com)
  • However, salvage esophagectomy is a highly invasive procedure with various postoperative complications compared to planned esophagectomy after neoadjuvant chemoradiotherapy (CRT). (springer.com)
  • Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ (2007) Salvage oesophagectomy after local failure of definitive chemoradiotherapy. (springer.com)
  • Definitive chemoradiotherapy (dCRT) represents a curative nonsurgical treatment option for patients with esophageal cancer. (ovid.com)
  • Details and Download Full Text PDF: Re-irradiation of locoregional esophageal cancer recurrence following definitive chemoradiotherapy: A report of 6 cases. (pubfacts.com)
  • A total of 6 patients who underwent re-irradiation for recurrence of locoregional esophageal cancer following definitive chemoradiotherapy were investigated. (pubfacts.com)
  • The aim of this study was to validate a new definition of borderline resectable pancreatic ductal adenocarcinoma (PDAC) provided by the 2017 international consensus on the basis of three dimensions of anatomical (A), biological (B), and conditional (C) factors, using the data of the patients who had been registered for our institutional protocol of chemoradiotherapy followed by surgery (CRTS) for localized patients with PDAC. (mdpi.com)
  • We examined whether pretreatment 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET), which can detect enhanced glucose uptake, was able to predict the therapeutic response to chemoradiotherapy (CRT) in patients with pancreatic cancer (PC). (springer.com)
  • In what researchers from the University Hospital in Madrid, Spain, are calling a practice-changing study, sequential treatment with chemotherapy followed by chemoradiotherapy more than doubled time-to-treatment failure in patients with unresectable locally advanced head and neck cancer. (hcplive.com)
  • Locoregional control, a secondary endpoint of the study, was seen in 61.5% of patients who received induction chemotherapy followed by chemoradiotherapy and in 44.5% of patients who received chemoradiotherapy alone (P = .002). (hcplive.com)
  • Chemoradiotherapy (CRT, CRTx, CT-RT) is the combination of chemotherapy and radiotherapy to treat cancer. (wikipedia.org)
  • Chemoradiotherapy as neoadjuvant therapy before surgery has been shown to be effective in esophageal cancer. (wikipedia.org)
  • Chemotherapy and chemoradiotherapy for rectal cancer. (wikipedia.org)
  • Compared with patients treated by surgery alone, patients receiving neoadjuvant chemoradiotherapy more likely obtained complete resection and had lower local cancer recurrence. (redorbit.com)
  • A study by Fogh et al of induction chemoradiotherapy followed by surgery, a strategy that is widely used in treating esophageal cancer, found that perioperative morbidity and mortality with this approach was not significantly different in patients aged 70 years or older compared with younger patients. (medscape.com)
  • The results of the review showed that women who had chemoradiotherapy for cervical cancer were likely to live for longer than women who had just radiotherapy. (cochrane.org)
  • Women who received chemoradiotherapy were also less likely to have the cancer come back or spread to other parts of the body. (cochrane.org)
  • After a 1999 National Cancer Institute (NCI) clinical alert was issued, chemoradiotherapy has become widely used in treating women with cervical cancer. (cochrane.org)
  • Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). (springer.com)
  • Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer. (bioportfolio.com)
  • Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. (nih.gov)
  • Changes in salivary flow rates in head and neck cancer after chemoradiotherapy. (biomedsearch.com)
  • Should Head and Neck Cancer Patients Receive Induction Chemotherapy Prior to Chemoradiotherapy? (hcplive.com)
  • Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer. (sigmaaldrich.com)
  • This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). (sigmaaldrich.com)
  • This phase I trial studies how well atezolizumab before and / or with standard of care chemoradiotherapy works in immune system activation in patients with stage IB2, II, IIIB, or IVA cervical cancer that has spread to the lymph nodes. (cancer.gov)
  • To evaluate the value of pretreatment inflammatory-nutritional biomarkers in predicting responses to neoadjuvant chemoradiotherapy (nCRT) and survival in patients with locally advanced rectal cancer (LARC). (frontiersin.org)
  • Cervical cancer (CC) is one of the acquired immunodeficiency syndrome (AIDS) defining diseases and the human immunodeficiency virus (HIV) infection is thought to relate with increased acute toxicity of chemoradiotherapy (CRT). (ovid.com)
  • The Locally advanced rectal cancer (LARC) patients were routinely treated with neoadjuvant chemoradiotherapy (CRT) firstly and received total excision afterwards. (spie.org)
  • Kermani AT, Bagheri R, Taheri H, Aliakbarian M, Soltani E, Joudi M. Evaluation of survival and recurrence patterns in esophageal cancer patients with pathological response to neoadjuvant chemoradiotherapy. (termedia.pl)
  • However, neoadjuvant chemoradiotherapy has been increasingly used in the treatment of esophageal cancer [4]. (termedia.pl)
  • A computer-assisted microvessel analysis system was developed to evaluate correlations between the architecture of biopsy specimen microvessels and the outcome for patients with esophageal cancer treated with chemoradiotherapy. (aacrjournals.org)
  • Biopsy specimens from 51 patients with esophageal cancer (T 2-3 , any N, M 0 ) treated with chemoradiotherapy were immunostained with an anti-CD31 antibody and quantified using computerized image analysis. (aacrjournals.org)
  • Computer-assisted tumor microvessel analysis is a powerful tool in predicting the outcome for patients with esophageal cancer treated with chemoradiotherapy because intraobserver and interobserver variability is minimized. (aacrjournals.org)
  • Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Database. (cancertherapyadvisor.com)
  • Here, inhibition of β-catenin by siRNAs or a small-molecule inhibitor (XAV-939) resulted in sensitization of colorectal cancer cells to chemoradiotherapy. (aacrjournals.org)
  • In summary, aberrant activation of Wnt/β-catenin signaling not only regulates the development and progression of colorectal cancer, but also mediates resistance of rectal cancers to chemoradiotherapy. (aacrjournals.org)
  • In the United Kingdom, patients with locally advanced rectal cancer routinely receive neoadjuvant chemoradiotherapy. (soton.ac.uk)
  • We prospectively studied 12 patients with rectal cancer who completed standardized neoadjuvant chemoradiotherapy, recruited from a large tertiary cancer centre, between October 2012 and July 2013. (soton.ac.uk)
  • Chemoradiotherapy (CRT) is a treatment standard in limited disease (LD) small cell lung cancer (SCLC). (jcancer.org)
  • A B S T R AC T BACKGROUND The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. (openaire.eu)
  • The researchers found that 92% of patients in the chemoradiotherapy-surgery group achieved complete resection with no tumor within 1mm of the resection margins, compared with 69% in the surgery-alone group. (empr.com)
  • This study is to assess the relationship between HPV tumor status and chemoradiotherapy (CRT) in PeCa locoregional control (LRC). (springer.com)
  • Because chemoradiotherapy can achieve similar survival rates to surgery or surgery combined with chemoradiotherapy, patient characteristics and tumor histologic features that favor chemoradiotherapy should be carefully assessed before choosing treatment. (aacrjournals.org)
  • Two miRNA ratios (miR-4521/miR-340-5p and miR-101-3p/miR-451a) that predicted the pathological response to neoadjuvant chemoradiotherapy were found to be associated with relapse-free survival. (springer.com)
  • Using both molecular and radiological findings, the investigators want to predict pathological response after chemoradiotherapy and to select patients who may benefit from treatment adjustments during chemoradiotherapy. (bioportfolio.com)
  • The Wnt-transcription factor, TCF7L2, is overexpressed in primary rectal cancers that are resistant to chemoradiotherapy and TCF7L2 mediates resistance to chemoradiotherapy. (aacrjournals.org)
  • To investigate the potential role of Wnt/β-catenin signaling in controlling therapeutic responsiveness, nontumorigenic RPE-1 cells were stimulated with Wnt-3a, a physiologic ligand of Frizzled receptors, which increased resistance to chemoradiotherapy. (aacrjournals.org)
  • This is called chemoradiotherapy (or chemoradiation). (cochrane.org)
  • This combined treatment is known as chemoradiotherapy (or chemoradiation). (healthtalk.org)
  • Twenty-nine percent of patients who underwent resection after chemoradiotherapy achieved a pathological complete response. (empr.com)
  • Proton chemoradiotherapy was associated with a significantly lower relative risk of 90-day side effects of at least grade 3, 90-day side effects of at least grade 2 and decline in performance status during treatment. (curetoday.com)
  • two deaths in the chemoradiotherapy group and one in the radiotherapy group were due to either intercurrent disease or late treatment-related toxicity. (ascopost.com)
  • It was recommended that patients in the induction chemotherapy group begin chemoradiotherapy within 21 to 28 days after the first day of the last cycle of induction chemotherapy. (ascopost.com)
  • The primary objective was the clinical complete response (cCR) rate after induction therapy plus chemoradiotherapy in intent-to-treat patients. (springermedizin.de)
  • For medically fit patients, perioperative neoadjuvant chemotherapy or chemoradiotherapy followed by surgery is appropriate. (medscape.com)
  • In the second randomization involving patients with progression-free disease after 4 months, 136 patients received 2 months of the same chemotherapy and 133 underwent chemoradiotherapy (54 Gy [a measure of radiation dose] plus the chemotherapy drug capecitabine). (brightsurf.com)
  • This single institutional retrospective study included patients who underwent chemoradiotherapy for clinical T1N0M0 ESCC using serum albumin concentrations and body weights evaluated pre- and post-chemoradiotherapy from January 2005 to December 2016. (dovepress.com)
  • Among the 492 patients with ESCC who underwent chemoradiotherapy, 44 were included in this study. (dovepress.com)
  • All patients underwent a cardiopulmonary exercise test and a phosphorus magnetic resonance spectroscopy quadriceps muscle exercise-recovery study before and after neoadjuvant chemoradiotherapy. (soton.ac.uk)
  • Patients with clinical T1N0M0 ESCC without dysphagia were at risk of undernutrition pre- and post-chemoradiotherapy. (dovepress.com)
  • Although it has been shown that chemoradiotherapy may induce immunogenic cell death, which could trigger T-cell immunity mediated by high-mobility group box 1 protein (HMGB1) and calreticulin, there is still limited information to support this theory directly in a clinical setting. (aacrjournals.org)
  • The clinical significance of this phenomenon in patients treated with chemoradiotherapy (CRT) remains unclear. (springermedizin.de)